<DOC>
	<DOCNO>NCT01060176</DOCNO>
	<brief_summary>Tranexamic acid think promise substitute aprotinin latter secede 2007 . Yet ideal dosage dose regimen tranexamic acid cardiopulmonary bypass cardiac surgery Chinese population remain controversial . The current study include patient receive valvular replacement coronary artery bypass surgery . Different dosage tranexamic acid deliver blood loss , transfusion clinical outcome record . The study hypothesis tranexamic acid could reduce blood loss allogeneic transfusion cardiopulmonary bypass cardiac surgery . Furthermore , tranexamic acid could decrease inflammatory reaction cardiac surgery .</brief_summary>
	<brief_title>Tranexamic Acid Blood Loss Transfusion Cardiac Surgery</brief_title>
	<detailed_description />
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>Rheumatic recessive valvular disease patient require valvular replacement surgery cardiopulmonary bypass Coronary artery disease patient require coronary artery bypass surgery cardiopulmonary bypass Nonprimary cardiac surgery Definite liver renal dysfunction Disorder coagulation function Drugs intervention influence inflammatory status ulinastatin Allergy Pregnancy lactation Disabled spirit law Fatal condition tumour</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>tranexamic acid</keyword>
	<keyword>cardiac surgery procedure</keyword>
	<keyword>hemostasis</keyword>
	<keyword>anti-inflammation</keyword>
</DOC>